Pleural Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pleural Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Pleural disorders encompass a spectrum of conditions affecting the protective tissue surrounding the lungs and lining the chest cavity. Within this category, three distinct types emerge—namely pleurisy, pleural effusion, and pneumothorax—each with diverse etiologies. Characterized by inflammation of the pleura, pleurisy stands as a primary manifestation. Conversely, pleural effusion and pneumothorax result from factors such as infection, medical conditions, or chest trauma, leading to the accumulation of fluid, pus, blood, or air or other gases within the pleural space. Common symptoms across all types include chest pain, shortness of breath, and coughing. Treatment approaches vary based on the specific disorder and its severity. Neglected, pleural disorders pose severe risks, potentially culminating in lung collapse, shock, or sepsis.
The Pleural Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Pleural Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pleural Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pleural Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 21 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pleural Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pleural Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pleural Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Aileron Therapeutics IncAmgen Inc
Biosyngen Pte Ltd
Boehringer Ingelheim International GmbH
Clover Biopharmaceuticals Ltd
Genelux Corp
GNI Group Ltd
Gongwin Biopharm Holdings Co Ltd
Hubei Soundny Bio-Tech Co Ltd
Jiangxi Jemincare Group Co Ltd
KARE Biosciences Inc
Lignamed LLC
Lipac Oncology LLC
Relief Therapeutics Holding AG
RS Oncology LLC
Simcere Pharmaceutical Group Ltd
Sino Biopharmaceutical Ltd
Vectus Biosystems Ltd
Wuhan Binhui Biopharmaceutical Co Ltd
Wuhan YZY Biopharma Co Ltd
Zhejiang Conba Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pleural Disease reports